Skip to main content

and
  1. No Access

    Article

    Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

    Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients1,2. In stage IV disease, the combination of ipilimumab + nivolumab is superior to ipil...

    Christian U. Blank, Elisa A. Rozeman, Lorenzo F. Fanchi in Nature Medicine (2018)

  2. No Access

    Article

    Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

    Expression of AXL earmarks melanoma cells resistant to BRAF and MEK inhibitors that either pre-exist in treatment-naive tumors or emerge in response to therapy. The combination of an AXL-MMAE antibody-drug con...

    Julia Boshuizen, Louise A Koopman, Oscar Krijgsman, Aida Shahrabi in Nature Medicine (2018)